The start-up has developed two new diagnostic tests ELISA and FAST FLOW SPOT to check neutralising activity of samples in response to the Covid-19 vaccination
ReaGene Innovations has developed the diagnostic tests with support from UoH Incubation centre, ASPIRE-BioNEST. (Credit: UoH Herald)
Indian healthcare start-up ReaGene Innovations has licensed its newly developed ELISA and FAST FLOW SPOT diagnostic tests to US-based Lay Science.
Incubated at the University of Hyderabad’s (UoH’s) incubation centre, ASPIRE BioNEST, ReaGene developed the tests to detect the neutralising activity of samples in response to Covid-19 vaccination.
According to the agreement, Lay Science will pay for the development of the two patent-pending diagnostics through commercialisation and the start-up will receive royalty payments upon the successful launch of the diagnostic tests.
The ELISA diagnostic test can examine numerous samples at the same time in any hospital and pathology lab setting.
The FAST FLOW SPOT diagnostic test is a one-time usage test that may be performed by anyone in their “home” environment.
Both diagnostic tests require a saliva sample whereas other existing tests assess neutralising antibodies in blood samples.
ReaGene Innovations scientific co-founder Dr Uday Saxena said: “Collaboration is important as it requires a concerted team effort to fight and win against a virus-like Covid-19 the likes of which we have never seen before.
“I am also delighted that with the support of Lays Science, we will be able to globally launch these two tests, and which will help us in our fight against Covid-19.”
Lay Science chief executive officer Dr Satish Chandran said: “These saliva-based ELISA and FAST FLOW SPOT diagnostic tests offer yet another line of defence against the onslaught of rapidly evolving SARS-CoV-2 viral variants.
“These two diagnostic tests are simple and easy-to-use, and this partnership reiterates Lays Sciences’ commitment to fighting Covid-19.”
Lay Science is engaged in providing novel solutions for the treatment and prevention of GI illnesses.
ImmunIgY, the company’s flagship product, is said to be the first-of-its-kind antibody-based oral medication intended to target the critical phase in Covid viral entrance and infection.